Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply
The company is pursuing specific goals in the areas of science and technology, value chain as well as climate and the environment.
Both the vaccines have been extensively tested by IVRI for safety and potency and have been found to provide 100% protection
Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF
Report outlines the wide array of investment opportunities in various segments of India’s healthcare sector
Pharma industry is ready to embrace technology platforms with a keen focus on automation in manufacturing and digital health investment.
A mix of favorable government policies and a positive environment will create a win-win situation for all stakeholders
Reflecting on the learning during the pandemic, industry is aiming to push innovation in R&D and implement automation and digital technologies across various operational levels.
Total incremental sales of Rs.2,94,000 crore and total incremental exports of Rs.1,96,000 crore are estimated during six years from 2022-23 to 2027-28.
The Govt. launched the PLI scheme for bulk drugs with a financial outlay of Rs 6,940 crores across 53 APIs over 6 years.
Subscribe To Our Newsletter & Stay Updated
